dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

April 23, 2020: Heidelberg Pharma AG

Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2020

  • Licensing partner Magenta announces MGTA-117 as the first ATAC candidate for clinical development
  • Telix receives FDA approval for TLX250-CDx to carry out Phase III clinical trial in the USA
  • MD Anderson Cancer Center and licensee Heidelberg Pharma are granted US patent for diagnosis and treatment of patients with TP53/RNA polymerase II deletion using ATAC technology
  • Heidelberg Pharma is granted European patent for amatoxin conjugates for tumor therapy
  • Heidelberg Pharma AG secures financing commitment of up to EUR 15 million from its main shareholder dievini
  • Financials developed in line with planning

Heidelberg Pharma AG, a company specializing in Antibody Targeted Amanitin Conjugates (ATACs), today reported on the first three months of fiscal year 2020 (1 December 2019 – 29 February 2020) and the Group’s financial figures.

Please read the whole article here

Heidelberg Pharma AG, News 2020
April 21, 2020: Cassiopea SpA
April 24, 2020: Joimax GmbH

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz